ResMed (RMD) Competitors

Stryker (NYSE:SYK) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Which has stronger valuation & earnings, SYK or RMD?

Stryker has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$21.97B	6.32	$3.17B	$9.33	39.03
ResMed	$4.81B	7.20	$1.02B	$7.55	31.24

Does the media prefer SYK or RMD?

In the previous week, Stryker had 32 more articles in the media than ResMed. MarketBeat recorded 43 mentions for Stryker and 11 mentions for ResMed. ResMed's average media sentiment score of 0.79 beat Stryker's score of 0.55 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stryker	15 Very Positive mention(s)	4 Positive mention(s)	20 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SYK or RMD a better dividend stock?

Stryker pays an annual dividend of $3.36 per share and has a dividend yield of 0.9%. ResMed pays an annual dividend of $2.12 per share and has a dividend yield of 0.9%. Stryker pays out 36.0% of its earnings in the form of a dividend. ResMed pays out 28.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 32 consecutive years and ResMed has raised its dividend for 13 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has more risk and volatility, SYK or RMD?

Stryker has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, ResMed has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Do analysts rate SYK or RMD?

Stryker currently has a consensus price target of $405.80, suggesting a potential upside of 11.43%. ResMed has a consensus price target of $227.91, suggesting a potential downside of 3.38%. Given Stryker's stronger consensus rating and higher possible upside, equities analysts clearly believe Stryker is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	0 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.81
ResMed	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.46

Does the MarketBeat Community prefer SYK or RMD?

Stryker received 500 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 64.73% of users gave Stryker an outperform vote while only 52.66% of users gave ResMed an outperform vote.

Company	Underperform	Outperform
Stryker	Outperform Votes 925 64.73%	Underperform Votes 504 35.27%
ResMed	Outperform Votes 425 52.66%	Underperform Votes 382 47.34%

Do insiders & institutionals have more ownership in SYK or RMD?

77.1% of Stryker shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 5.5% of Stryker shares are owned by company insiders. Comparatively, 0.7% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is SYK or RMD more profitable?

ResMed has a net margin of 23.15% compared to Stryker's net margin of 16.34%. ResMed's return on equity of 25.53% beat Stryker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stryker	16.34%	23.07%	11.04%
ResMed	23.15%	25.53%	17.59%

Summary

Stryker beats ResMed on 15 of the 22 factors compared between the two stocks.